Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
15.18
-0.15 (-0.98%)
Apr 23, 2025, 4:00 PM EDT - Market closed

Takeda Pharmaceutical Statistics

Total Valuation

Takeda Pharmaceutical has a market cap or net worth of $46.38 billion. The enterprise value is $81.09 billion.

Market Cap 46.38B
Enterprise Value 81.09B

Important Dates

The next confirmed earnings date is Thursday, May 8, 2025, before market open.

Earnings Date May 8, 2025
Ex-Dividend Date Mar 31, 2025

Share Statistics

Takeda Pharmaceutical has 1.59 billion shares outstanding. The number of shares has increased by 1.17% in one year.

Current Share Class n/a
Shares Outstanding 1.59B
Shares Change (YoY) +1.17%
Shares Change (QoQ) -1.52%
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float 1.52B

Valuation Ratios

The trailing PE ratio is 35.05.

PE Ratio 35.05
Forward PE n/a
PS Ratio 1.59
Forward PS 0.02
PB Ratio 0.98
P/TBV Ratio n/a
P/FCF Ratio 7.24
P/OCF Ratio 6.55
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.08, with an EV/FCF ratio of 12.66.

EV / Earnings 61.27
EV / Sales 2.78
EV / EBITDA 10.08
EV / EBIT 21.62
EV / FCF 12.66

Financial Position

The company has a current ratio of 1.31, with a Debt / Equity ratio of 0.73.

Current Ratio 1.31
Quick Ratio 0.59
Debt / Equity 0.73
Debt / EBITDA 4.13
Debt / FCF 5.39
Interest Coverage 6.57

Financial Efficiency

Return on equity (ROE) is 2.94% and return on invested capital (ROIC) is 2.97%.

Return on Equity (ROE) 2.94%
Return on Assets (ROA) 2.51%
Return on Invested Capital (ROIC) 2.97%
Return on Capital Employed (ROCE) 4.53%
Revenue Per Employee $590,997
Profits Per Employee $26,854
Employee Count 49,281
Asset Turnover 0.31
Inventory Turnover 1.31

Taxes

In the past 12 months, Takeda Pharmaceutical has paid $169.28 million in taxes.

Income Tax 169.28M
Effective Tax Rate 11.33%

Stock Price Statistics

The stock price has increased by +13.62% in the last 52 weeks. The beta is 0.34, so Takeda Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y) 0.34
52-Week Price Change +13.62%
50-Day Moving Average 14.61
200-Day Moving Average 14.05
Relative Strength Index (RSI) 59.50
Average Volume (20 Days) 2,453,531

Short Selling Information

Short Interest 5.03M
Short Previous Month 4.31M
Short % of Shares Out 0.32%
Short % of Float 0.33%
Short Ratio (days to cover) 3.10

Income Statement

In the last 12 months, Takeda Pharmaceutical had revenue of $29.12 billion and earned $1.32 billion in profits. Earnings per share was $0.83.

Revenue 29.12B
Gross Profit 19.04B
Operating Income 3.75B
Pretax Income 366.81M
Net Income 1.32B
EBITDA 8.04B
EBIT 3.75B
Earnings Per Share (EPS) $0.83
Full Income Statement

Balance Sheet

The company has $3.14 billion in cash and $34.55 billion in debt, giving a net cash position of -$31.40 billion or -$19.81 per share.

Cash & Cash Equivalents 3.14B
Total Debt 34.55B
Net Cash -31.40B
Net Cash Per Share -$19.81
Equity (Book Value) 47.19B
Book Value Per Share 29.77
Working Capital 4.17B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $7.08 billion and capital expenditures -$1.25 billion, giving a free cash flow of $6.40 billion.

Operating Cash Flow 7.08B
Capital Expenditures -1.25B
Free Cash Flow 6.40B
FCF Per Share $4.04
Full Cash Flow Statement

Margins

Gross margin is 65.38%, with operating and profit margins of 12.88% and 4.54%.

Gross Margin 65.38%
Operating Margin 12.88%
Pretax Margin 5.13%
Profit Margin 4.54%
EBITDA Margin 27.62%
EBIT Margin 12.88%
FCF Margin 21.99%

Dividends & Yields

This stock pays an annual dividend of $0.59, which amounts to a dividend yield of 3.88%.

Dividend Per Share $0.59
Dividend Yield 3.88%
Dividend Growth (YoY) 17.55%
Years of Dividend Growth n/a
Payout Ratio 71.16%
Buyback Yield -1.17%
Shareholder Yield 2.71%
Earnings Yield 2.85%
FCF Yield 13.81%
Dividend Details

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Takeda Pharmaceutical has an Altman Z-Score of 1.12 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 1.12
Piotroski F-Score 6